BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kram M. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World J Hepatol 2023; 15(2): 201-207 [PMID: 36926236 DOI: 10.4254/wjh.v15.i2.201]
URL: https://www.wjgnet.com/1007-9327/full/v15/i2/201.htm
Number Citing Articles
1
Anna Lisa Cammarota, Antonia Falco, Anna Basile, Carlo Molino, Massimiliano Chetta, Gianni D’Angelo, Liberato Marzullo, Margot De Marco, Maria Caterina Turco, Alessandra Rosati. Pancreatic Cancer-Secreted Proteins: Targeting Their Functions in Tumor MicroenvironmentCancers 2023; 15(19): 4825 doi: 10.3390/cancers15194825
2
Shifang Tang, Jürgen Borlak. Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failuresHepatology 2024;  doi: 10.1097/HEP.0000000000000780
3
Yasmin Mohtasham Kia, Alessandro Cannavo, Pegah Bahiraie, Sanam Alilou, Behrad Saeedian, Nastaran Babajani, Elina Ghondaghsaz, Amirmohammad Khalaji, Amir Hossein Behnoush, Sowjanya Thatikonda. Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial FibrillationDisease Markers 2023; 2023: 1 doi: 10.1155/2023/2097012
4
Jorge Arnold, Francisco Idalsoaga, Luis Antonio Díaz, Daniel Cabrera, Francisco Barrera, Juan Pablo Arab, Marco Arrese. Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the HorizonCurrent Hepatology Reports 2024; 23(1): 204 doi: 10.1007/s11901-023-00629-0